- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05769322
Real World Data Analysis: Impact of High-Frequency REN Treatments as Migraine Preventive Therapy in Adolescence
Remote Electrical Neuromodulation (REN) Wearable Device for Adolescents With Migraine: Real World Study of High-Frequency Users Suggest Preventive Effects
Study Overview
Detailed Description
The REN device (Nerivio by Theranica, ISRAEL) is a neuromodulation device approved by the FDA for acute and/or preventive treatment of migraine in patients of 12 years old and above. It is a wearable device applied to the upper arm. It stimulates C and Aδ noxious fibers using a modulated, symmetrical, biphasic, square pulse with a pulse width of 400 μs, modulated frequency of 100-120 Hz, and up to 40 mA output current which the patient can adjust. The REN device is operated by a designated app that is downloaded to the user's phone prior first use of the Nerivio device.
As part of the sign-up process to the Nerivio app, all patients accept the terms of use which specify that providing personal information is done by their own free will and that their de-identified data may be used for research purposes. Users are not obligated to provide personal information and could treat without providing any feedback. The app includes a secured, personal migraine diary, which enables patients to record and track their migraines and other headaches. At the beginning of each treatment, and again 2 hours after the start of treatment, patients are prompted to record their symptoms, including pain level (none, mild, moderate, severe), functional disability (No limitation, Some limitation, Moderate limitation, Severe limitation), and an indication of which medications, if any, were taken within that 2-hour time window.
This post-marketing RWE study investigates the potential of high usage of Nerivio for the acute treatment of migraine on migraine prevention, using the following outcomes:
- - reduction in mean monthly migraine treatment days (MMTD),
- - acute treatment efficacy measured 2 h post-treatment
- - improve in functional disability
- - Device safety
Together, these objectives may provide a comprehensive evaluation of the impact of the high usage of Nerivio for acute treatment as a migraine preventive tool in the migraine adolescent population.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Dagan Harris, PhD
- Phone Number: +972-73-3703649
- Email: daganh@theranica.com
Study Contact Backup
- Name: Alit Stark Inbar, PhD
- Phone Number: +972-73-3703649
- Email: alitsi@theranica.com
Study Locations
-
-
-
Netanya, Israel, 4250438
- Theranica BioElectronics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patient age is 12 Years to 18 Years
- Patient is using the Nerivio device for acute treatment of migraine
- Patient treated at least 10 treatments in his first month of using Nerivio and at least 3 treatments in each of the two consecutive months (months 2 and 3
Exclusion Criteria:
- Treatments shorter than 30 minutes
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Mean Monthly Migraine Treatment Days
Time Frame: 3 months
|
Mean number of migraine treatment days per month during 3 consecutive months, comparing each month to the first month. A migraine treatment day is defined as a day in which a patient treated their migraine with REN. |
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Consistent Headache Relief at 2 Hours Post-treatment
Time Frame: 2 hours
|
The proportion of subjects reporting headache relief at 2 hours post-treatment in at least 50% of all their treatments. headache relief is defined as an improvement from severe or moderate pain to mild or no pain. Pain level is reported using a 4-point Likert scale (0 - No pain, 1 - Mild pain, 2 - Moderate pain,3- Severe pain) |
2 hours
|
Consistent Freedom From Headache at 2 Hours Post-treatment
Time Frame: 2 hours
|
The proportion of subjects reporting freedom from headache at 2 hours post-treatment in at least 50% of all their treatments. Pain freedom is defined as the disappearance of headache from severe, moderate, or mild headache at treatment initiation to no headache 2 hours later. Pain level is reported using a 4-point Likert scale (0 - No pain, 1 - Mild pain, 2 - Moderate pain,3- Severe pain). |
2 hours
|
Consistent Functional Disability Relief at 2 Hours Post-treatment
Time Frame: 2 hours
|
The proportion of subjects who reported having Functional Disability at the beginning of the treatment and reported improvement of at least one level of Functional Disability at 2 hours post-treatment in at least 50% of all their treatments. Functional Disability level is reported using a 4-point Likert scale (0 - No limitation, 1 - Some limitation, 2 - Moderate limitation, 3 - Severe limitation). |
2 hours
|
Consistent Functional Disability disappearance at 2 Hours Post-treatment
Time Frame: 2 hours
|
The proportion of subjects who reported having Functional Disability at the beginning of the treatment and reported no Functional Disability at 2 hours post-treatment in at least 50% of all their treatments. Functional Disability level is reported using a 4-point Likert scale (0 - No limitation, 1 - Some limitation, 2 - Moderate limitation, 3 - Severe limitation). |
2 hours
|
Device Related Adverse Events
Time Frame: 3 months
|
Incidence of device-related adverse events reported by subjects
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alit Stark Inbar, PhD, Theranica Bio-Electronics Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RWE005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
CoolTech LLCObvioHealthRecruitingMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
Norwegian University of Science and TechnologyAstraZeneca; St. Olavs Hospital; Kragerø Tablettproduksjon as, NorwayCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraNorway
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Nerivio
-
TheranicaTerminated
-
TheranicaActive, not recruiting
-
TheranicaCompleted
-
Children's National Research InstituteTheranicaRecruitingNew Daily Persistent Headache (NDPH)United States
-
TheranicaCompleted
-
TheranicaCompletedMenstrual MigraineUnited States
-
TheranicaNot yet recruitingMigraine in Children
-
TheranicaCompletedMigraine Without Aura | Migraine With AuraIsrael
-
TheranicaCompletedMigraine in AdolescenceIsrael
-
TheranicaCompletedChronic MigraineUnited States